Haleon PLC, a firm specializing in consumer-health wearables, has witnessed a series of events. Despite a
slowing expansion and some insiders selling off shares, the firm's
dividend remains secure. Notably in 2026, a significant recovery could shape Haleon's future. Scharf Investments LLC holds an impressive $11.08 million in Haleon, while other brokerage firms such as
Jefferies maintain a buy rating on the stock.
There have been major changes in shareholdings with significant buybacks leading to almost
8.9 million shares cancelled and 7.8 million shares repurchased for cancellation.
The company saw a
3% organic growth in 2025, largely attributed to its 'Win as One' strategy, which promises a bright future for the company. However, share prices experience fluctuations due to factors such as Q4 sales missing targets and the offering of cautious guidance for 2026. Haleon has also invested £65m in a new toothpaste plant to cater to the Chinese adult demographics suffering from gum issues. The biotech firm also partners with life science companies for strategic growth.
Haleon Stocks News Analytics from Thu, 01 May 2025 07:00:00 GMT to Sat, 04 Apr 2026 10:48:35 GMT -
Innovation 0
- Rumor -3
